As we have seen today with abingdons share price going up around 40% with a DHSC settlement of only £6.3 million . You can bet your bottom dollar that once our dispute for over 10 x that amount is settled our share price will rise multiples of that !!
Talk Agent Selection and Master Protocols for Evaluation of Candidate COVID-19 Therapeutics and Lessons Learned for Future Pandemics Working in an unprecedented timeframe, the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership rapidly designed a unique therapeutic agent intake and assessment process for multiple types of candidate treatments (preclinical and clinical antivirals, immune modulators, SARS-CoV-2 neutralizing antibodies, and organ supportive) for COVID-19, reviewing over 800 and advancing over 30 agents to trials for testing. ACTIV also developed and launched ten master protocols between April 2020 and August 2021 to allow for the coordinated and efficient evaluation of these over 30 investigational therapeutic agents. The ACTIV master protocols were designed with a portfolio approach to serve multiple patient populations with COVID-19: outpatient mild to moderately ill, inpatient moderately ill, and inpatient critically ill and designed to test the spectrum of the disease pathophysiology. Each protocol, either adaptive or pragmatic, was designed to efficiently select those treatments that provide benefit to patients while rapidly eliminating those that were either not effective or safe. For both the agent prioritization and master protocol development ACTIV has captured lessons learned that may be useful in meeting the challenges of a future pandemic.
Stacey Adam Biography Stacey plays a leadership role at the FNIH, helping to lead many public-private partnerships, such as Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) the PPP that evaluated hundreds of available therapeutic agents with potential application for COVID-19, prioritized them, and designed and launched multiple master protocols to test them. Stacey oversees the Cancer, Metabolic Diseases and Clinical COVID Research portfolios at the Foundation for the National Institute of Health (FNIH). Beyond ACTIV other major partnerships under her guidance include the two steering committees of the Biomarkers Consortium and their projects, Partnership for Accelerating Cancer Therapies (PACT), and the Lung Master protocol (Lung-MAP) clinical trial. Prior to FNIH, she was a Manager at Deloitte Consulting within the Federal Life Sciences and Healthcare Strategy. She received her PhD at Duke and postdoctoral training at Stanford.
Pi100, if you are not invested here and hate the share so much why do you spend so much time on this board constantly moaning ? Try sharing a bit of positive research like my griproom article ;) Or honour the bet you made with harchris and clear off . Your credibility is shot to pieces old boy . What , what .
However there are factors that could easily arise and change this SP drastically for the better . Things can change quickly and with only 72 million shares available this can fly given the right circumstances .
As winter approaches and we are already seeing a surge in covid cases in the U.K. and the world a large order may drop in our favour at any time.
This rise is also based on many millions LESS tests than this time last year so many cases go undetected .
Tata md express PCR could become a very popular diagnostics tool in India and we may see many multiple units deployed and sold in India .
Our monkey pox tests may well be being prepared for sale for the WHO and unicef . ( we were first responders with our covid tests ) it could happen again .
A DHSC resolution or compromise to inject many more millions into our bank balance .
The list goes on .
You could be waiting until you retire or any of the above could happen by Christmas .
You and only you have the choice of when to press that button ..